COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
UK releases security strategy and plans for future defence spending boost
The UK’s National Security Strategy brings together the recently released Strategic Defence Review (SDR), Strategic Security Review, AUKUS Review and Industrial and Trade Strategies. At the same time, the UK made a commitment to reach defence spending of 5% of GDP by 2035 and Germany committed to 3.5% by 2029.
-
Pentagon’s FY26 defence budget proposal is $130 billion more than US Congress plans to provide
The House Committee on Appropriations approved a FY2026 bill reducing investments in main defence programmes.
-
What role could holographic and 3D capabilities play in the warfare of tomorrow
Holographic and 3D technologies have been lauded by some for their ability to provide technical and operational advantages for military training and planning. But is the hype truly justified?
-
Unfolding the Golden Dome for America: Seven things you should know about the programme
Shephard talked to multiple experts about the most pressing concerns and considerations regarding the air defence system advocated by President Trump.
-
Industry welcomes UK Strategic Defence Review, but pressure remains on future defence investment plans
While industry reception to the SDR has been positive, questions still remain from analyst and trade associations about what this could mean for future investment and the future UK Defence Industrial Strategy.